PX; BTW...did you ever take a look at VRAL ? Since you're in the pharma sector as a profession (as I recall ?) , I'd be interested in your take on that one.....looks very promising to me , especially considering who's on their BOD:
Viral Genetics, Inc. is a biotechnology company that discovers and develops immune-based therapies for HIV and AIDS using its thymus nuclear protein compound. This compound may have other potential applications for other infectious, autoimmune, and immunological deficiency diseases that the company intends to study in the future. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity profile, simple dosing regimen, and short-course of treatment.
Our management team, board and advisors include world-renowned experts in the fight against HIV/AIDS, infectious disease, and autoimmune deficiency.
================================================================
VRAL BOARD: An amazing assortment of premier intellectual and medical talent.
**Luc Montagnier ****Co Discoverer of the HIV Virus****
Dr. Montagnier is best known for his 1983 discovery of the human immunodeficiency virus (HIV), which has been identified as the cause of AIDS. This discovery led directly to the development of a test for detecting the presence of HIV in blood samples. He has received more than 20 major awards, including the Commandeur de la Legion d'Honneur, the Lasker Award, the Gairdner Award, King Faisal Foundation International Prize(known as the Arab Nobel Prize),and this year's Nobel Prize in Physiology or Medicine awarded to him for the discovery of HIV.
He is the co-founder of the World Foundation for AIDS Research and Prevention and co-directs the Program for International Viral Collaboration.
As President of the World Foundation for Aids Research and Prevention, he has co-founded two centers for the prevention, treatment, research and diagnosis of AIDS patients in Ivory Coast and Cameroon.
**Charles Everett Koop , past Surgeon General of the U.S. , was born in Brooklyn, New York on October 14, 1916. He obtained his B.A. degree from Dartmouth College in 1937 and his M.D. degree from Cornell Medical School in 1941. After interning at the Pennsylvania Hospital, Dr. Koop pursued postgraduate training at the University Of Pennsylvania School Of Medicine, Boston Children’s Hospital and the Graduate School of Medicine at U. of Pennsylvania, where he obtained a D.Sc. Degree in 1947.
“Dr. Koop’s treatment of HIV / AIDS as a public health issue rather than a moral issue was a major breakthrough. The report and mailing educated the public on the magnitude of the epidemic, which garnered support for new research and methods of treatment,” said Monica Ord, SVP of corporate development and communications for Viral Genetics, Inc.
**Eric S. Rosenberg, MD, Chairman
Dr. Rosenberg has an extensive background studying HIV. He is best known for his research on early HIV infection, also known as primary HIV infection. His important findings of immune control of HIV infection during structured treatment interruptions in primary infection were previously published and highly cited in journals, including Science and Nature. Dr. Rosenberg is board-certified in Internal Medicine and Infectious Diseases. His research and clinical practice is focused on the immunopathogenesis of HIV infection with additional work related to infectious disease and transplant medicine. Dr. Rosenberg is an Assistant Professor of Medicine at Harvard Medical School, where he has been appointed in various academic capacities since 1995, and is a Staff Physician at the Massachusetts General Hospital in Boston, where he has also been appointed since 1995. He serves in the capacities of Associate Director of the Clinical Microbiology Laboratory, and Director of the Education Unit of the Clinical Research Program at Massachusetts General Hospital.
**Marshall C. Phelps, Jr. is currently Corporate Vice President for IP Policy and Strategy for Microsoft. In this position, Mr. Phelps is responsible for establishing global policy and strategy for Microsoft's intellectual property, and interfacing with governments and technology companies about intellectual property issues. During his tenure at Microsoft he has also overseen management of the company's trademark, copyright, patent, trade secret and related divisions. Prior to Microsoft, Mr. Phelps spent 28 years at IBM where he served as vice president for intellectual property and licensing. At IBM, Phelps oversaw the company's patent licensing program and intellectual property portfolio development amongst other things.
In between IBM and Microsoft, Mr. Phelps spent two years as chairman and chief executive officer of Spencer Trask Intellectual Capital Company LLC, which specialized in spin-offs from major corporations such as Motorola Inc., Lockheed Martin Corp. and IBM. Phelps holds a Bachelor of Arts degree from Muskingum College, a Master of Science degree from Stanford Graduate School of Business and a doctorate from Cornell Law School. He is an Executive-in-Residence at the Fuqua School of Business at Duke University, and also serves on the Board of Visitors. He has also recently been asked to advise Japan's Ministry of Economy, Trade and Industry on IP matters and was elected to the initial class of the Intellectual Property Hall of Fame, in 2006.
**Richard T. Gerstner joins Viral Genetics as an Advisor after a lifetime of executive management positions and investment in the technology arena. Gerstner spent several years as President and CEO of Telular Corporation, a wireless communication company he took public in the 1990s. Prior to that, he spent 32 years at IBM in several capacities including 10 years as a Corporate Vice President during which he served as Chief Planning Officer, Head of the Asia/Pacific region located in Tokyo and Group Executive of IBM Personal Computers, and most recently as head of IBM's PC Group.
----------------------------------------------------------------------------------
**In addition; They may have a good shot at getting "Fast-track" FDA status for their drug. They are also debt-free & have a multi-faceted approach to optimizing the many applications for this proprietary tech including , licensing to others ASAP.
aimho
----------------------------------------------------------------------------------
p.s. Good to hear from you too...hope all is well up there in No. Calif.
.
News 
Market Data 
Discover 
